# Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans

> **NCT07492173** · NA · COMPLETED · sponsor: **Shandong New Time Pharmaceutical Co., LTD** · enrollment: 76 (actual)

## Conditions studied

- Solid Tumor Cancer

## Interventions

- **DRUG:** Trifluridine and Tipiracil Tablets
- **DRUG:** Lonsurf®

## Key facts

- **NCT ID:** NCT07492173
- **Lead sponsor:** Shandong New Time Pharmaceutical Co., LTD
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-11-21
- **Primary completion:** 2023-06-25
- **Final completion:** 2023-06-25
- **Target enrollment:** 76 (ACTUAL)
- **Last updated:** 2026-03-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07492173

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07492173, "Bioequivalence Study of Trifluridine and Tipiracil Hydrochloride Tablets on Fasting and Fed in Humans". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07492173. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*